突触相关基因集罕见损伤突变对中国精神分裂症患者短期抗精神病药疗效的影响:一项随机临床试验
该多中心开放标签随机临床试验纳入3023例中国汉族精神分裂症患者,接受6周抗精神病药治疗;对316例极好与极差应答者行全外显子测序,并在1920例独立样本中靶向测序验证。发现无应答组中「降低NMDA介导突触电流」和「降低AMPA介导突触电流」两个基因集富集罕见损伤突变,其中NMDA基因集在独立样本中重复验证;不同抗精神病药之间疗效无统计学显著差异。
要点
- 无应答组富集降低NMDA及AMPA介导突触电流基因集的罕见损伤突变。
- 降低NMDA介导突触电流基因集在独立样本靶向测序中获重复验证。
- 不同抗精神病药物之间未发现疗效的统计学显著差异。
核心结论
- 谷氨酸能或NMDA神经传递的遗传变异与短期抗精神病药疗效相关。
- 全外显子测序或可用于药物基因组学中的罕见遗传变异研究。
研究设计与样本
- 患者随机接受5种非典型和2种典型抗精神病药中的一种,疗程6周。
- 对316例按6周PANSS总分减分率分组的极好应答者(n=156)与无应答者(n=160)行全外显子测序。
- 在1920例独立样本中以靶向测序进行验证。
- 数据分析于2016年3月15日至2017年3月1日进行。
主要发现
- 3023例患者中女性1549例(51.24%)、男性1474例(48.8%),平均(SD)年龄31.2(7.9)岁。
- 2336例(77.3%)符合遗传分析条件;质控排除后316例(10.5%)纳入全外显子测序,1920例(63.5%)纳入重复验证。
- 全外显子测序发现阶段,无应答组中「降低NMDA介导突触电流」和「降低AMPA介导突触电流」两个基因集富集罕见损伤突变。
- 「降低NMDA介导突触电流」基因集在独立样本靶向测序中获重复验证。
- 接受不同抗精神病药物的患者之间未发现抗精神病药应答的统计学显著差异。
关键数值与推荐
- 疗效主要结局为第6周PANSS评分较基线的变化。
- 全外显子测序对象为6周治疗后按PANSS总分减分率判定的极好应答者(n=156)与无应答者(n=160)。
- 重复验证样本为1920例独立患者,采用靶向测序。
临床怎么用
- 提示谷氨酸能/NMDA传递相关罕见遗传变异可能参与短期抗精神病药疗效差异。
- 全外显子测序可作为精神药物基因组学中研究罕见变异的候选方法。
- 不同抗精神病药之间疗效未见显著差异,药物选择仍需结合其他临床因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The underlying mechanism for individual differences in patient response to antipsychotic medication remains unknown. OBJECTIVE: To discover genes and gene sets harboring rare variants associated with short-term antipsychotic medication efficacy. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label, randomized clinical trial conducted between July 6, 2010, and December 31, 2011, 3023 patients recruited in China of Chinese Han descent with schizophrenia with total Positive and Negative Syndrome Scale (PANSS) score ≥ 60 received a 6-week treatment of antipsychotic medications randomly chosen from 5 atypical and 2 typical antipsychotic medications. Whole-exome sequencing (WES) was performed in 316 participants (grouped into those with the best response [n=156] and those who had no response [n=160] to the antipsychotic medication prescribed), according to the total PANSS score reduction rate after 6 weeks of treatment. Validation was performed using targeted sequencing in an independent sample of 1920 patients. Data analyses was performed between March 15, 2016, and March 1, 2017. MAIN OUTCOMES AND MEASURES: Drug efficacy at week 6 was assessed according to the change in PANSS scores from baseline. Extremely good and extremely poor responders were selected for an initial WES association study, from which a subset of genes showing putative association was selected for independent replication with a targeted sequencing approach. RESULTS: Of the 3023 patients (1549 [51.24%] female and 1474 [48.8%] male; mean [SD] age, 31.2 [7.9] years), 2336 (77.3%) were eligible for genetic analysis. After quality-control exclusions, 316 patients (10.5%) were included for WES and 1920 (63.5%) were included for replication. In the WES discovery stage, 2 gene sets (reduced NMDA [N-methyl-D-aspartate]-mediated synaptic currents and reduced AMPA [α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid]-mediated synaptic currents) were found to be enriched with rare damaging variants in the nonresponder group, suggesting the involvement of these gene sets in antipsychotic medication efficacy. Reduced NMDA-mediated synaptic currents gene set was further replicated in an independent sample using targeting sequencing. No statistically significant differences in antipsychotic drug response were found among the patients who received different antipsychotic drugs. CONCLUSIONS AND RELEVANCE: Genetic variation in glutamatergic or NMDA neurotransmission is implicated in short-term antipsychotic medication efficacy; WES may have utility in the study of rare genetic variation in pharmacogenetics. TRIAL REGISTRATION: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934.
引用
- Wang Q, Man Wu H, Yue W, et al. Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 30422257. doi:10.1001/jamapsychiatry.2018.3039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。